Here it is the very FIRST Afrezza Users “Real Life” Results Group that will demonstrate how Afrezza really works in the REAL-WORLD! Every week we will compile our data and present it to you to be able to share it and learn from what we are doing. Best of luck to every Afrezza User out there!
What surprises you most about the first week data?
The obvious for me is that our time in zone was significantly greater than anyone expected. Also, the A1C’s levels we are running at now are considered “non-diabetic” or “pre-diabetic”. Of course, this number needs to be run for 12 weeks before any of the participants can claim an A1C in 5’s or low 6’s. You should know that none of us have ever had an A1c that low. We are all stunned, as will our doctors be when we do get that 3 month A1C number. Note: Dr. Bode did look at my data from my Dexcom Monitor and it was only for the first 4 weeks and used the word “unbelievable” several times. On the trials I finished with an A1C of 7.1 even with all the protocols. Can’t wait to see other doctors reaction around the country when all the Afrezza users officially report their #’s – doctors will be pleasantly shocked. And then this new drug Afrezza will be everywhere and a common prescription for all diabetics (except for smokers, asthma sufferers and persons with COPD)
What is the Afrezza Users “Real Life” Results Group?
It is a group of Afrezza Users who use a Continuous Glucose Monitors (Type 1’s) seeking tighter diabetes control and measuring the time spent in each blood sugar range. It is NOT a competition and was only started so people could understand and see the inherent benefit of why Afrezza provides better control and higher patient satisfaction for t1 and t2 diabetics over our previous regimens.
Why are you doing this?
There has been so much discussion about the FDA Afrezza Drug trials and why I feel as a participant in the Affinity 1 trial, there were significant “hold backs” as to why we were not able to materially outperform Injectable Insulin because of the protocols on the trials. This is no longer the case!
To Summarize just a few:
- Afrezza Dosing only changed approx. every 6 weeks, not flexible
- No CGM’s allowed
- Time in Zone not measured
- Patient quality of life not measured
- Brand new users vs. Very experienced users (what if it was brand new injectable users vs. experienced Afrezza users—would that be fair? No-both require learning curve)
What would you like to express to everyone out there considering Afrezza or to any doctors considering prescribing Afrezza for their patients?
My opinion is that Afrezza is a “life-changing” drug that is not very well understood by the diabetic community at large—both doctors and patients. It improved my life and gave me hope in treating my diabetes. I would wish the same for any other diabetic out there—a better and higher quality of life!